BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sridharan M, Go RS, Abraham RS, Fervenza FC, Sethi S, Bryant SC, Spears GM, Murray DL, Willrich MAV. Diagnostic Utility of Complement Serology for Atypical Hemolytic Uremic Syndrome. Mayo Clin Proc 2018;93:1351-62. [PMID: 30286829 DOI: 10.1016/j.mayocp.2018.07.008] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Raina R, Vijayvargiya N, Khooblall A, Melachuri M, Deshpande S, Sharma D, Mathur K, Arora M, Sethi SK, Sandhu S. Pediatric Atypical Hemolytic Uremic Syndrome Advances. Cells 2021;10:3580. [PMID: 34944087 DOI: 10.3390/cells10123580] [Reference Citation Analysis]
2 Bray MA, Sartain SE, Gollamudi J, Rumbaut RE. Microvascular thrombosis: experimental and clinical implications. Transl Res 2020;225:105-30. [PMID: 32454092 DOI: 10.1016/j.trsl.2020.05.006] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 10.0] [Reference Citation Analysis]
3 Sridharan M, Kluge ML, Go RS, Abraham RS, Moyer AM. Challenges in classification of novel CFH variants in patients with atypical hemolytic uremic syndrome. Thrombosis Update 2020;1:100002. [DOI: 10.1016/j.tru.2020.100002] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Shi W, Lv J, Lin L. Coagulopathy in COVID-19: Focus on vascular thrombotic events. J Mol Cell Cardiol 2020;146:32-40. [PMID: 32681845 DOI: 10.1016/j.yjmcc.2020.07.003] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 10.0] [Reference Citation Analysis]
5 Thurman JM. Complement Biomarkers of Hemolytic Uremic Syndrome-If Not One Thing, Maybe Another. Mayo Clin Proc 2018;93:1337-9. [PMID: 30286826 DOI: 10.1016/j.mayocp.2018.08.024] [Reference Citation Analysis]
6 Sridharan M, Hook CC, Leung N, Winters JL, Go RS; Mayo Clinic Complement Alternative Pathway-Thrombotic Microangiopathy Disease-Oriented Group. Postsurgical thrombotic microangiopathy: Case series and review of the literature. Eur J Haematol 2019;103:307-18. [PMID: 31251415 DOI: 10.1111/ejh.13284] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
7 Palma LMP, Sridharan M, Sethi S. Complement in Secondary Thrombotic Microangiopathy. Kidney Int Rep 2021;6:11-23. [PMID: 33102952 DOI: 10.1016/j.ekir.2020.10.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
8 Husain D, Barron B, Barron AG, Sandokji I, Marsenic O, Warejko JK. Atypical hemolytic uremic syndrome due to DGKE mutation and response to eculizumab: lessons for the clinical nephrologist. J Nephrol 2021;34:1331-5. [PMID: 33751496 DOI: 10.1007/s40620-020-00925-8] [Reference Citation Analysis]
9 Raina R, Sethi SK, Dragon-Durey MA, Khooblall A, Sharma D, Khandelwal P, Shapiro R, Boyer O, Yap HK, Bagga A, Licht C. Systematic review of atypical hemolytic uremic syndrome biomarkers. Pediatr Nephrol 2022. [PMID: 35118546 DOI: 10.1007/s00467-022-05451-2] [Reference Citation Analysis]